Navigation Links
Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
Date:12/4/2007

pletion of enrollment of the trial triggers a milestone payment from JDRF under this agreement.

About SB-509

SB-509 is a formulation of a zinc finger DNA-binding protein transcription factor (ZFP TF) designed to upregulate the expression of the gene encoding vascular endothelial growth factor (VEGF-A). Sangamo is currently evaluating this ZFP Therapeutic in a second ongoing Phase 2 clinical trial for the treatment of moderate to severe DN; plans to initiate a third Phase 2 trial to evaluate the effect of SB-509 on the mobilization of stem cells in subjects with DN; and has a preclinical program targeting spinal cord injury. Sangamo has also announced a new clinical program, the initiation of a Phase 2 clinical trial in Amyotrophic Lateral Sclerosis (Lou Gehrig's disease) in the first half of 2008.

Phase 2 study of SB-509 for mild to moderate DN

The clinical trial is a double-blind, placebo-controlled, repeat-dosing study designed to evaluate the clinical safety and clinical effects of repeat administration of SB-509 in diabetics with mild to moderate diabetic peripheral sensory motor neuropathy in the legs.

A total of 102 subjects have been enrolled into the trial. Subjects were randomized to one of two groups in a 2:1 ratio. The larger group is being treated by intramuscular injection of 60 mg of SB-509 (30 mg of SB-509 per leg) into the lower limb every 2 months. The remaining group is receiving an equal volume of placebo on the same schedule. Each subject will receive a total of three treatments (Day 0, 60 and 120). Subjects will receive injections in a distribution pattern that targets the skeletal muscle adjacent to the major peripheral nerves in the legs and feet.

The symptoms of diabetic peripheral neuropathy and any changes that occur during the trial will be evaluated based on neurological examination data, electrophysiological testing data, subject neurological questionnaire, and subject pain assessment. Investigat
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
2. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
3. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
4. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
8. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
9. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
10. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
11. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 As health officials across the ... select Meijer pharmacies in Michigan will ... eligible patients, enabling Meijer pharmacists to administer tests and, in ... by a physician participating in the study. The ...
(Date:1/15/2014)... N.J. , Jan. 15, 2014  Celsion Corporation (the "Company") ... has received commitments from institutional investors to purchase an ... stock in an at-the-market registered direct offering, led by ... entered into definitive purchase agreements with these investors pursuant ...
(Date:1/15/2014)... 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will ... Journal of Drugs in Dermatology (JDD) at ... The event is January 17-20, 2014, at the Omni Orlando Resort ... The ODAC is a distinguished event that ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
... 1 Allen Medical Systems, a Hill-Rom company, (NYSE: ... Spotlight Series showcasing interviews with top orthopaedic surgeons. Carlos ... Institute, is the featured surgeon and is recognized for ... Intraoperative Arm Positioner for elbow fractures, scopes and clavicle ...
... Therapeutics, Inc. (OTC Bulletin Board: ECTE), a ... as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) ... delivery, announced today that Patrick T. Mooney, M.D., Chairman ... Annual JMP Securities Healthcare Conference on Tuesday, October 6, ...
Cached Medicine Technology:Allen Medical Systems Announces Surgeon Spotlight Series Interview 2Allen Medical Systems Announces Surgeon Spotlight Series Interview 3Echo Therapeutics to Present at 4th Annual JMP Securities Healthcare Conference 2
(Date:7/10/2014)... CLEVELAND The U.S. Department of Health and Human ... Hospitals (UH) Case Medical Center Seidman Cancer Center totaling ... at improving care for patients with complex cancer. ... a unique model developed at UH to enhance care ... or demonstrated need for high health care utilization. ...
(Date:7/10/2014)... Up to 70% of Parkinson,s disease (PD) ... quality of life. Some patients have disturbed sleep/wake ... asleep, while other patients may be subject to ... extreme, PD patients may exhibit REM-sleep behavior disorder ... re-enactment, even before motor symptoms appear. A review ...
(Date:7/10/2014)... Katerina Alba,s research at the University of Huddersfield could ... most popular emulsion-based food products such as butter, ... starting to gain an international profile for her work. ... food science at the University and now she has ... her supervisor, Dr Vassilis Kontogiorgos, she is investigating the ...
(Date:7/10/2014)... 10, 2014) A research review identifying the clinical ... first step in the process of developing evidence-based guidelines ... new report published by Neurosurgery , ... Surgeons . The journal is published by Lippincott ... Wolters Kluwer Health . , Based on analysis ...
(Date:7/10/2014)... Spring Harbor, NY For decades, health-conscious people around ... rich in antioxidants, figuring this was one of the ... , Yet clinical trials of antioxidant supplements have ... hoping to reduce their cancer risk. Virtually all ... against cancer. In fact, in several trials antioxidant ...
Breaking Medicine News(10 mins):Health News:UH Case Medical Center awarded $4.7 million grant from HHS 2Health News:UH Case Medical Center awarded $4.7 million grant from HHS 3Health News:Sleep disturbances, common in Parkinson's disease, can be early indicator of disease onset 2Health News:World interest in research work on the benefits of the Okra plant 2Health News:What's a concussion? Review identifies four evidence-based indicators 2Health News:What's a concussion? Review identifies four evidence-based indicators 3Health News:How antioxidants can accelerate cancers, and why they don't protect against them 2
... and amoxicillin when it comes to treating ailments like ... effective. Doctors, who reviewed the treatment given to // ... the newer drugs is more effective than the traditional ... ,Pediatricians at the University of Rochester Medical Center found ...
... treatment by Andrew Lamerton, a vascular surgeon, until he ... lead to the patient being confined to a wheelchair. ... only aggravated Smith’s condition, and he would feel better ... County Hospital supported the doctor, as the National Institute ...
... A new research has revealed that happiness results ... The Psychological Bulletin of the American Psychological Association ... reinforcing positive emotions, which also motivates people to ... ,Dr. Sonja Lyubomirsky of the University ...
... awareness regarding beauty and body solutions, the demand for ... steadily over the recent years. The healthy competition amongst ... has not only resulted in improved outcomes but also ... was previously underdeveloped when compared to the other Indian ...
... during the course of the winter and fall months, from ... to overcome the seasonal affective disorder (SAD), and the people ... ,Those who suffer from SAD overeat, sleep a lot, and ... and develop an aversion to social interactions. The lesser sunlight ...
... anti-inflammatory drug Bextra, meant for those who suffer from arthritis. ... cardiovascular risks, including the possibility of // triggering strokes and ... ,The drug is also known to cause severe skin ... earlier withdrawn the drug which belongs to the cox-2 inhibitors ...
Cached Medicine News:Health News:Penicillin To Pave Way For New Antibiotics 2Health News:Happiness Plays An Important Role In Success 2Health News:New Plastic Surgery Unit Set Up In Kolkata To Meet Ever-Increasing Consumer Demand 2
... order products are offered as 1-piece or ... The modular instruments may be customized with ... as ratchets, insulation and flush ports. Many ... Customer specifications may affect delivery times. ...
... Featured Products are kept ... and are offered as ... regular or extra long ... with insulation, flush ports, ...
... AEM Laparoscopic Instruments incorporate a layered design ... shielded and monitored to prevent stray electrosurgical ... caused by insulation failure or capacitive coupling; ... shield built into all AEM Instruments provides ...
... incorporate a layered design unique in the ... to prevent stray electrosurgical burns along the ... failure or capacitive coupling; a well-documented patient ... all AEM Instruments provides a neutral return ...
Medicine Products: